OPKO Health, Inc. – Product Pipeline Review

Global Markets Direct’s, ‘OPKO Health, Inc. – Product Pipeline Review – 2016’, provides an overview of the OPKO Health, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by OPKO Health, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of OPKO Health, Inc.

The report provides overview of OPKO Health, Inc. including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses OPKO Health, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features OPKO Health, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate OPKO Health, Inc.’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for OPKO Health, Inc.

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding OPKO Health, Inc.’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 6

OPKO Health, Inc. Snapshot 7

OPKO Health, Inc. Overview 7

Key Information 7

Key Facts 7

OPKO Health, Inc. - Research and Development Overview 8

Key Therapeutic Areas 8

OPKO Health, Inc. - Pipeline Review 11

Pipeline Products by Stage of Development 11

Pipeline Products - Monotherapy 12

Pipeline Products - Combination Treatment Modalities 13

Pipeline Products - Out-Licensed Products 14

Out-Licensed Products/Combination Treatment Modalities 15

OPKO Health, Inc. - Pipeline Products Glance 16

OPKO Health, Inc. - Late Stage Pipeline Products 16

Filing rejected/Withdrawn Products/Combination Treatment Modalities 16

Phase III Products/Combination Treatment Modalities 17

OPKO Health, Inc. - Clinical Stage Pipeline Products 18

Phase II Products/Combination Treatment Modalities 18

Phase I Products/Combination Treatment Modalities 19

OPKO Health, Inc. - Early Stage Pipeline Products 20

Preclinical Products/Combination Treatment Modalities 20

Discovery Products/Combination Treatment Modalities 21

OPKO Health, Inc. - Unknown Stage Pipeline Products 22

Unknown Products/Combination Treatment Modalities 22

OPKO Health, Inc. - Drug Profiles 23

calcifediol MR 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

fermagate 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

MOD-4023 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

CTAP-201 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

lunacalcipol 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

MOD-5014 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

MOD-6031 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

CTA-091 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

CUR-1916 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

MOD-1001 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

MOD-1002 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

MOD-6030 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

MOD-7023 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

MOD-9013 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

MOD-9017 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

Oligonucleotide for Mucopolysaccharidosis I 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Oligonucleotide For Rett Syndrome 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecule for Hearing Loss 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecule for Oncology 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

Small Molecules to Inhibit Phosphate Transport for Hyperphosphatemia In CKD 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

SR-3306 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Recombinant Protein for Atherosclerosis 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

Recombinant Protein for Rheumatoid Arthritis 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Small Molecules to Inhibit Lipoprotein Signal Peptidase for Bacterial Infections 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

OPK-0018 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

OPKO Health, Inc. - Pipeline Analysis 55

OPKO Health, Inc. - Pipeline Products by Target 55

OPKO Health, Inc. - Pipeline Products by Route of Administration 57

OPKO Health, Inc. - Pipeline Products by Molecule Type 58

OPKO Health, Inc. - Pipeline Products by Mechanism of Action 59

OPKO Health, Inc. - Recent Pipeline Updates 61

OPKO Health, Inc. - Dormant Projects 76

OPKO Health, Inc. - Company Statement 77

OPKO Health, Inc. - Locations And Subsidiaries 78

Head Office 78

Other Locations & Subsidiaries 78

Appendix 80

Methodology 80

Coverage 80

Secondary Research 80

Primary Research 80

Expert Panel Validation 80

Contact Us 80

Disclaimer 81

List of Tables

List of Tables

OPKO Health, Inc., Key Information 7

OPKO Health, Inc., Key Facts 7

OPKO Health, Inc. – Pipeline by Indication, 2016 9

OPKO Health, Inc. – Pipeline by Stage of Development, 2016 11

OPKO Health, Inc. – Monotherapy Products in Pipeline, 2016 12

OPKO Health, Inc. – Combination Treatment Modalities in Pipeline, 2016 13

OPKO Health, Inc. – Out-Licensed Products in Pipeline, 2016 14

OPKO Health, Inc. – Out-Licensed Products/ Combination Treatment Modalities, 2016 15

OPKO Health, Inc. – Filing rejected/Withdrawn, 2016 16

OPKO Health, Inc. – Phase III, 2016 17

OPKO Health, Inc. – Phase II, 2016 18

OPKO Health, Inc. – Phase I, 2016 19

OPKO Health, Inc. – Preclinical, 2016 20

OPKO Health, Inc. – Discovery, 2016 21

OPKO Health, Inc. – Unknown, 2016 22

OPKO Health, Inc. – Pipeline by Target, 2016 55

OPKO Health, Inc. – Pipeline by Route of Administration, 2016 57

OPKO Health, Inc. – Pipeline by Molecule Type, 2016 58

OPKO Health, Inc. – Pipeline Products by Mechanism of Action, 2016 60

OPKO Health, Inc. – Recent Pipeline Updates, 2016 61

OPKO Health, Inc. – Dormant Developmental Projects,2016 76

OPKO Health, Inc., Subsidiaries 78

List of Figures

List of Figures

OPKO Health, Inc. – Pipeline by Top 10 Indication, 2016 9

OPKO Health, Inc. – Pipeline by Stage of Development, 2016 11

OPKO Health, Inc. – Monotherapy Products in Pipeline, 2016 12

OPKO Health, Inc. – Out-Licensed Products in Pipeline, 2016 14

OPKO Health, Inc. – Pipeline by Top 10 Target, 2016 55

OPKO Health, Inc. – Pipeline by Route of Administration, 2016 57

OPKO Health, Inc. – Pipeline by Molecule Type, 2016 58

OPKO Health, Inc. – Pipeline Products by Top 10 Mechanism of Action, 2016 59

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports